Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pirenoxine→

Pirenoxine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1043-21-6
Molecular formula
C16H8N2O5
Molecular weight
308.24 g/mol
Drug class
Ophthalmic anti-cataract agentquinone-opacification inhibitor
Mechanism of action
Competes with quinone compounds implicated in oxidation and insolubilisation of water-soluble lens proteins. It is intended to maintain lens protein solubility and retard progression of early lens opacity; evidence of clinical benefit is limited and product use is jurisdiction-specific.
Indications / reported uses
  • Topical ophthalmic treatment intended to retard progression of early senile cataract in Japan and selected Asian markets; this is not a treatment for advanced cataract or a substitute for surgery.

Sources: https://www.rad-ar.or.jp/siori/english/search/result?n=1575 · https://www.kegg.jp/medicus-bin/japic_med?japic_code=00069142 · https://www.data-index.co.jp/medsearch/ethicaldrugs/searchresult/detail/?trk_toroku_code=1319706Q3043 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pirenoxine Environmental Risk Assessment (ERA) (the Pirenoxine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.